Citius Oncology, Inc.
CTOR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $938 | $3,139 | $1,265 | $1,296 |
| G&A Expenses | $4,007 | $4,332 | $5,130 | $5,373 |
| SG&A Expenses | $4,007 | $4,332 | $5,130 | $5,373 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,945 | $7,471 | $6,395 | $6,669 |
| Operating Income | -$4,945 | -$7,471 | -$6,395 | -$6,669 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$161 | $0 | $0 | $0 |
| Pre-Tax Income | -$5,106 | -$7,471 | -$6,395 | -$6,669 |
| Tax Expense | $264 | $264 | $264 | $144 |
| Net Income | -$5,370 | -$7,736 | -$6,659 | -$6,813 |
| % Margin | – | – | – | – |
| EPS | -0.075 | -0.11 | -0.093 | -0.098 |
| % Growth | 31.8% | -18.2% | 4.7% | – |
| EPS Diluted | -0.075 | -0.11 | -0.093 | -0.098 |
| Weighted Avg Shares Out | 71,552 | 71,552 | 71,552 | 71,552 |
| Weighted Avg Shares Out Dil | 71,552 | 71,552 | 71,552 | 71,552 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $161 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4,945 | -$7,471 | -$6,395 | -$6,669 |
| % Margin | – | – | – | – |